These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 38496700)

  • 1. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.
    Mao X; Lee NK; Saad SE; Fong IL
    Transl Lung Cancer Res; 2024 Feb; 13(2):375-397. PubMed ID: 38496700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancing cancer therapy: new frontiers in targeting DNA damage response.
    Qian J; Liao G; Chen M; Peng RW; Yan X; Du J; Huang R; Pan M; Lin Y; Gong X; Xu G; Zheng B; Chen C; Yang Z
    Front Pharmacol; 2024; 15():1474337. PubMed ID: 39372203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
    Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
    J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
    Wang M; Chen S; Ao D
    MedComm (2020); 2021 Dec; 2(4):654-691. PubMed ID: 34977872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State-of-the-art strategies for targeting the DNA damage response in cancer.
    Pilié PG; Tang C; Mills GB; Yap TA
    Nat Rev Clin Oncol; 2019 Feb; 16(2):81-104. PubMed ID: 30356138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
    Gachechiladze M; Skarda J; Bouchalova K; Soltermann A; Joerger M
    Front Oncol; 2020; 10():581217. PubMed ID: 33224881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.
    Martorana F; Da Silva LA; Sessa C; Colombo I
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the DNA Damage Response Machinery for Lung Cancer Treatment.
    Venugopala KN
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving DNA repair synthetic lethality targets in cancer.
    Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
    Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting DNA Damage Response in Prostate and Breast Cancer.
    Wengner AM; Scholz A; Haendler B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Targeting of DNA Damage Response in Cancer.
    Choi W; Lee ES
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
    Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
    Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Damage Repair Inhibitors-Combination Therapies.
    Smith G; Alholm Z; Coleman RL; Monk BJ
    Cancer J; 2021 Nov-Dec 01; 27(6):501-505. PubMed ID: 34904813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting DNA damage repair pathways in pancreas cancer.
    Crowley F; Park W; O'Reilly EM
    Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the DNA damage response for cancer therapy.
    Curtin NJ
    Biochem Soc Trans; 2023 Feb; 51(1):207-221. PubMed ID: 36606678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
    Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
    Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
    Sun W; Zhang Q; Wang R; Li Y; Sun Y; Yang L
    Front Oncol; 2021; 11():648687. PubMed ID: 34026622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer.
    Deng S; Vlatkovic T; Li M; Zhan T; Veldwijk MR; Herskind C
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.